Cargando…
Search-and-replace genome editing without double-strand breaks or donor DNA
Most genetic variants that contribute to disease(1) are challenging to correct efficiently and without excess byproducts(2–5). Here we describe prime editing, a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a catalytically im...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907074/ https://www.ncbi.nlm.nih.gov/pubmed/31634902 http://dx.doi.org/10.1038/s41586-019-1711-4 |
_version_ | 1783478477366755328 |
---|---|
author | Anzalone, Andrew V. Randolph, Peyton B. Davis, Jessie R. Sousa, Alexander A. Koblan, Luke W. Levy, Jonathan M. Chen, Peter J. Wilson, Christopher Newby, Gregory A. Raguram, Aditya Liu, David R. |
author_facet | Anzalone, Andrew V. Randolph, Peyton B. Davis, Jessie R. Sousa, Alexander A. Koblan, Luke W. Levy, Jonathan M. Chen, Peter J. Wilson, Christopher Newby, Gregory A. Raguram, Aditya Liu, David R. |
author_sort | Anzalone, Andrew V. |
collection | PubMed |
description | Most genetic variants that contribute to disease(1) are challenging to correct efficiently and without excess byproducts(2–5). Here we describe prime editing, a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a catalytically impaired Cas9 fused to an engineered reverse transcriptase, programmed with a prime editing guide RNA (pegRNA) that both specifies the target site and encodes the desired edit. We performed >175 edits in human cells including targeted insertions, deletions, and all 12 types of point mutations without requiring double-strand breaks or donor DNA templates. We applied prime editing in human cells to correct efficiently and with few byproducts the primary genetic causes of sickle cell disease (requiring a transversion in HBB) and Tay-Sachs disease (requiring a deletion in HEXA), to install a protective transversion in PRNP, and to precisely insert various tags and epitopes into target loci. Four human cell lines and primary post-mitotic mouse cortical neurons support prime editing with varying efficiencies. Prime editing shows higher or similar efficiency and fewer byproducts than homology-directed repair, complementary strengths and weaknesses compared to base editing, and much lower off-target editing than Cas9 nuclease at known Cas9 off-target sites. Prime editing substantially expands the scope and capabilities of genome editing, and in principle can correct up to 89% of known genetic variants associated with human diseases. |
format | Online Article Text |
id | pubmed-6907074 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-69070742020-04-21 Search-and-replace genome editing without double-strand breaks or donor DNA Anzalone, Andrew V. Randolph, Peyton B. Davis, Jessie R. Sousa, Alexander A. Koblan, Luke W. Levy, Jonathan M. Chen, Peter J. Wilson, Christopher Newby, Gregory A. Raguram, Aditya Liu, David R. Nature Article Most genetic variants that contribute to disease(1) are challenging to correct efficiently and without excess byproducts(2–5). Here we describe prime editing, a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a catalytically impaired Cas9 fused to an engineered reverse transcriptase, programmed with a prime editing guide RNA (pegRNA) that both specifies the target site and encodes the desired edit. We performed >175 edits in human cells including targeted insertions, deletions, and all 12 types of point mutations without requiring double-strand breaks or donor DNA templates. We applied prime editing in human cells to correct efficiently and with few byproducts the primary genetic causes of sickle cell disease (requiring a transversion in HBB) and Tay-Sachs disease (requiring a deletion in HEXA), to install a protective transversion in PRNP, and to precisely insert various tags and epitopes into target loci. Four human cell lines and primary post-mitotic mouse cortical neurons support prime editing with varying efficiencies. Prime editing shows higher or similar efficiency and fewer byproducts than homology-directed repair, complementary strengths and weaknesses compared to base editing, and much lower off-target editing than Cas9 nuclease at known Cas9 off-target sites. Prime editing substantially expands the scope and capabilities of genome editing, and in principle can correct up to 89% of known genetic variants associated with human diseases. 2019-12 2019-10-21 /pmc/articles/PMC6907074/ /pubmed/31634902 http://dx.doi.org/10.1038/s41586-019-1711-4 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Anzalone, Andrew V. Randolph, Peyton B. Davis, Jessie R. Sousa, Alexander A. Koblan, Luke W. Levy, Jonathan M. Chen, Peter J. Wilson, Christopher Newby, Gregory A. Raguram, Aditya Liu, David R. Search-and-replace genome editing without double-strand breaks or donor DNA |
title | Search-and-replace genome editing without double-strand breaks or
donor DNA |
title_full | Search-and-replace genome editing without double-strand breaks or
donor DNA |
title_fullStr | Search-and-replace genome editing without double-strand breaks or
donor DNA |
title_full_unstemmed | Search-and-replace genome editing without double-strand breaks or
donor DNA |
title_short | Search-and-replace genome editing without double-strand breaks or
donor DNA |
title_sort | search-and-replace genome editing without double-strand breaks or
donor dna |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907074/ https://www.ncbi.nlm.nih.gov/pubmed/31634902 http://dx.doi.org/10.1038/s41586-019-1711-4 |
work_keys_str_mv | AT anzaloneandrewv searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna AT randolphpeytonb searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna AT davisjessier searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna AT sousaalexandera searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna AT koblanlukew searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna AT levyjonathanm searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna AT chenpeterj searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna AT wilsonchristopher searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna AT newbygregorya searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna AT raguramaditya searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna AT liudavidr searchandreplacegenomeeditingwithoutdoublestrandbreaksordonordna |